Canada: Aphria triples production capacity

Aphria has received a license amendment from Health Canada that provides the company with additional production space of 57,000 square feet, as part of its Part II expansion at its facility in Leamington, Ontario. This will more than triple Aphria’s production capacity of medical cannabis from 2,600 kgs annually to 8,000 kgs annually.

The Health Canada license amendment falls under the Access to Cannabis for Medical Purposes Regulations. The first crop cultivated and produced at the Part II expansion will be available for sale in the middle of August.

“The license amendment marks the completion of the second part of Aphria’s four-part expansion plan, set to be completed by July 2018,” said Vic Neufeld, Chief Executive Officer, Aphria. “This will allow us to continue to produce high-quality cannabis at one of the lowest costs in the industry. The expansion will propel Aphria’s greenhouse footprint to become the largest in the industry and deliver on our long-term strategic plan.”

For more information:
Aphria Inc.
Vic Neufeld
President & CEO
1-844-427-4742
aphria.com